Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Headache Pain
2022 May 26;231:59. doi: 10.1186/s10194-022-01425-9.
Show Gene links
Show Anatomy links
Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor.
Hage La Cour S
,
Juhler K
,
Kogelman LJA
,
Olesen J
,
Klærke DA
,
Kristensen DM
,
Jansen-Olesen I
.
???displayArticle.abstract???
BACKGROUND: The clinical use of calcitonin gene-related peptide receptor (CGRP-R) antagonists and monoclonal antibodies against CGRP and CGRP-R has offered new treatment possibilities for migraine patients. CGRP activates both the CGRP-R and structurally related amylin 1 receptor (AMY1-R). The relative effect of erenumab and the small-molecule CGRP-R antagonist, rimegepant, towards the CGRP-R and AMY-R needs to be further characterized.
METHODS: The effect of CGRP and two CGRP-R antagonists were examined in Xenopus laevis oocytes expressing human CGRP-R, human AMY1-R and their subunits.
RESULTS: CGRP administered to receptor expressing oocytes induced a concentration-dependent increase in current with the order of potency CGRP-R> > AMY1-R > calcitonin receptor (CTR). There was no effect on single components of the CGRP-R; calcitonin receptor-like receptor and receptor activity-modifying protein 1. Amylin was only effective on AMY1-R and CTR. Inhibition potencies (pIC50 values) for erenumab on CGRP induced currents were 10.86 and 9.35 for CGRP-R and AMY1-R, respectively. Rimegepant inhibited CGRP induced currents with pIC50 values of 11.30 and 9.91 for CGRP-R and AMY1-R, respectively.
CONCLUSION: Our results demonstrate that erenumab and rimegepant are potent antagonists of CGRP-R and AMY1-R with 32- and 25-times preference for the CGRP-R over the AMY1-R, respectively. It is discussed if this difference in affinity between the two receptors is the likely reason why constipation is a common and serious adverse effect during CGRP-R antagonism but less so with CGRP binding antibodies.
Bhakta,
Migraine therapeutics differentially modulate the CGRP pathway.
2021, Pubmed
Bhakta,
Migraine therapeutics differentially modulate the CGRP pathway.
2021,
Pubmed
Booms,
MCF-7 as a Model for Functional Analysis of Breast Cancer Risk Variants.
2019,
Pubmed
Cooper,
Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease.
1994,
Pubmed
Cottrell,
Localization of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) in human gastrointestinal tract.
2012,
Pubmed
Dodick,
CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
2019,
Pubmed
Dos Santos,
Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
2022,
Pubmed
Eftekhari,
Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system.
2013,
Pubmed
Eftekhari,
Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion.
2010,
Pubmed
Falkenberg,
Two-Hour CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment.
2020,
Pubmed
Gates,
Calcitonin gene-related peptide-alpha receptor binding sites in the gastrointestinal tract.
1989,
Pubmed
Grider,
CGRP as a transmitter in the sensory pathway mediating peristaltic reflex.
1994,
Pubmed
Hargreaves,
Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
2019,
Pubmed
Hay,
Amylin: Pharmacology, Physiology, and Clinical Potential.
2015,
Pubmed
Hay,
Amylin receptors: molecular composition and pharmacology.
2004,
Pubmed
Hay,
Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
2005,
Pubmed
Holzer,
Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide's Motor-Stimulating and Prosecretory Function in the Intestine.
2021,
Pubmed
Jansen-Olesen,
In-depth characterization of CGRP receptors in human intracranial arteries.
2003,
Pubmed
Jansen-Olesen,
Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase.
1996,
Pubmed
Jespersen,
Dual-function vector for protein expression in both mammalian cells and Xenopus laevis oocytes.
2002,
Pubmed
,
Xenbase
Kanaan,
Real-world effectiveness and tolerability of erenumab: A retrospective cohort study.
2020,
Pubmed
King,
Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor.
2019,
Pubmed
Kraenzlin,
Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones.
1985,
Pubmed
Lambru,
A prospective real-world analysis of erenumab in refractory chronic migraine.
2020,
Pubmed
Liberini,
Amylin receptor components and the leptin receptor are co-expressed in single rat area postrema neurons.
2016,
Pubmed
McLatchie,
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.
1998,
Pubmed
,
Xenbase
Mulder,
Islet amyloid polypeptide in the gut and pancreas: localization, ontogeny and gut motility effects.
1997,
Pubmed
Pan,
Antagonism of CGRP Signaling by Rimegepant at Two Receptors.
2020,
Pubmed
Shi,
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.
2016,
Pubmed
Szkutnik-Fiedler,
Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies.
2020,
Pubmed
Uddman,
Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects.
1986,
Pubmed
Vu,
Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects.
2017,
Pubmed
Walker,
A second trigeminal CGRP receptor: function and expression of the AMY1 receptor.
2015,
Pubmed
Walker,
CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured.
2018,
Pubmed
Warfvinge,
Distribution of CGRP and CGRP receptor components in the rat brain.
2019,
Pubmed
Wattiez,
Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting.
2020,
Pubmed
Young,
Inhibition of gastric emptying.
2005,
Pubmed
Zimmermann,
Coexistence of novel amylin-binding sites with calcitonin receptors in human breast carcinoma MCF-7 cells.
1997,
Pubmed
de Vries Lentsch,
Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study.
2021,
Pubmed
ter Haar,
Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism.
2010,
Pubmed
